Abstract
Trichomonas vaginalis is a sexually transmitted protozoan parasite of humans. Treatment of trichomoniasis is almost completely dependent on the old drug metronidazole and is hampered by resistance. New drug development, like routine screening for drug resistance, has however been hampered by the lack of reliable screening protocols with sufficient throughput. Here we report on two separate in vitro protocols that use fluorescent dyes and allow for standardized drug sensitivity testing on the required scale.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Poole DN, McClelland RS (2013) Global epidemiology of Trichomonas vaginalis. Sex Transm Infect 89:418–422
McClelland RS et al (2007) Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 195:698–702
Cotch MF et al (1997) Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 24:353–360
Bachmann LH et al (2011) Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis 53(Suppl 3):S160–S172
Dunne RL et al (2003) Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 13:239–249
Miller MR, Nyirjesy P (2011) Refractory trichomoniasis in HIV-positive and HIV-negative subjects. Curr Infect Dis Rep 13:595–603
Diamond LS (1957) The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 43:488–490
Clark CG, Diamond LS (2002) Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev 15:329–341
Giordani RB et al (2009) Anti-Trichomonas vaginalis activity of synthetic lipophilic diamine and amino alcohol derivatives. Biomed Pharmacother 63:613–617
Campos Aldrete ME et al (2005) A high-throughput colorimetric and fluorometric microassay for the evaluation of nitroimidazole derivatives anti-Trichomonas activity. Toxicol In Vitro 19:1045–1050
Duarte M et al (2009) A quantitative resazurin assay to determinate the viability of Trichomonas vaginalis and the cytotoxicity of organic solvents and surfactant agents. Exp Parasitol 123:195–198
Natto MJ et al (2012) Validation of novel fluorescence assays for the routine screening of drug susceptibilities of Trichomonas vaginalis. J Antimicrob Chemother 67:933–943
Acknowledgements
This work was supported through a Research Fellowship from the Government of Saudi Arabia to M.J.N. (grant number S8306) and a Commonwealth scholarship to A.A.E.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Natto, M.J., Eze, A.A., de Koning, H.P. (2015). Protocols for the Routine Screening of Drug Sensitivity in the Human Parasite Trichomonas vaginalis . In: Hempel, J., Williams, C., Hong, C. (eds) Chemical Biology. Methods in Molecular Biology, vol 1263. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2269-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2269-7_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2268-0
Online ISBN: 978-1-4939-2269-7
eBook Packages: Springer Protocols